Description
ULTOMIRIS is a complement inhibitor indicated for:
• The treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). The treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit
complement-mediated thrombotic microangiopathy (TMA).
Limitations of Use:
ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
• The treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
• The treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive.
Additional information
| Brand | ULTOMIRIS® |
|---|---|
| Generic name | Ravulizumab-cwvz for injection |
| Form | Parenteral |
| Strength | 300mg/3mL |
| Manufacturer | Alexion Pharmaceuticals |
| Documents | Either PO or prescription |
| Storage | 2-8°C temperature |
| Global delivery time | 10-20 days |
| Pay attention | Shipment should be organized from our Company with airlines only (Not FedEx, DHL, EMS, Aramex, UPS), at the specified storage condition along with one data logger. |
| Shipping type | Drop-shipping / direct shipping |
Related products
-
-
+ wishlist+ compare
Besponsa Injection 1mg
Original price was: $9,182.00.$6,656.00Current price is: $6,656.00.Add to cart -
-
Reviews
There are no reviews yet.